<DOC>
	<DOC>NCT00765947</DOC>
	<brief_summary>This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure [msSBP] ≥ 140 mmHg and &lt; 180 mmHg and/or mean sitting Diastolic Blood Pressure [msDBP] ≥ 90 and &lt;110 mmHg).</brief_summary>
	<brief_title>Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Outpatients ≥ 18 years of age Patients with a diagnosis of mild to moderate hypertension at Visit 1 All patients must have a msSBP ≥ 140 mmHg and &lt; 180 mmHg and/or msDBP ≥ 90 mmHg and &lt; 110 mmHg mmHg at Visit 3 Severe hypertension defined as msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg Secondary form of hypertension Current diagnosis of heart failure (NYHA Class IIIV) Current angina pectoris requiring pharmacological therapy (other than stable doses of oral or topical nitrates) Second or third degree heart block without a pacemaker Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial fibrillation or atrial flutter, during the 12 months prior to Visit 1 Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Essential Hypertension ( mild to moderate)</keyword>
</DOC>